Erythema Multiforme in an HIV+ Patient on Highly Active Antiretroviral Therapy After Starting Paxlovid (Nirmatrelvir-Ritonivir)
Alison D Cáceres, Kristy Bono, Neil Kothari
TL;DR
An HIV+ patient developed erythema multiforme after taking Paxlovid for COVID-19, with symptoms improving only slightly.
Contribution
This case highlights a possible link between Paxlovid and erythema multiforme in HIV+ patients.
Findings
The patient developed oral and cutaneous lesions resembling erythema multiforme after Paxlovid treatment.
Intravenous steroids and antihistamines provided only mild improvement.
Biopsy and infectious workup did not reveal an alternative cause.
Abstract
In this report, we present a case of a woman currently on HIV antiretroviral therapy who presented with oral mucosal and cutaneous skin lesions with a target-like appearance following completion of a five-day course of Paxlovid™ for symptomatic COVID-19 infection. The patient was treated with intravenous steroids and oral antihistamines with mild improvement. However, she returned in one week with worsening skin lesions. The biopsy and infectious workup were non-contributory. It was determined that the patient had developed erythema multiforme (EM), secondary to Paxlovid™.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDrug-Induced Adverse Reactions · Dermatological and COVID-19 studies · Parvovirus B19 Infection Studies